Menu Search
Equities

Kodiak Sciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
K27:MUN

Kodiak Sciences Inc

Actions
  • Price (EUR)18.06
  • Today's Change-1.19 / -6.18%
  • Shares traded45.00
  • 1 Year change+221.07%
  • Beta2.6490
Data delayed at least 15 minutes, as of Feb 06 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

  • Revenue in USD (TTM)0.00
  • Net income in USD-217.34m
  • Incorporated2009
  • Employees123.00
  • Location
    Kodiak Sciences Inc1250 Page Mill RdPALO ALTO 94304United StatesUSA
  • Phone+1 (650) 281-0850
  • Fax+1 (302) 636-5454
  • Websitehttps://kodiak.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.